Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

-current portion of equipment

financing 1,352,684 955,695

Deferred rent and other non-current

liabilities 1,576,734 1,464,902

Total liabilities 11,851,683 12,472,671

Commitments

Stockholders' equity:

Common stock 3,437 2,944

Additional paid-in capital 320,579,240 298,073,896

Deferred stock-based compensation (251,601) (1,006,604)

Accumulated other comprehensive

income (loss) 69,262 (21,376)

Accumulated deficit (279,006,083) (240,245,163)

Total stockholders' equity 41,394,255 56,803,697

Total liabilities and stockholders'

equity $53,245,938 $69,276,368

Note 1: The condensed balance sheet at December 31, 2006 has been

derived from the audited financial statements at that date

included in the Company's Form 10-K for the fiscal year ended

December 31, 2006.

SUNESIS PHARMACEUTICALS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Three months ended Twelve months ended

December 31, December 31,

2007 2006 2007 2006

Revenue:

Collaboration

revenue $37,500 $229,167 $1,576,610 $6,353,585

Collaboration

revenue from

related party 1,759,208 1,725,810 7,586,903 7,317,700

License revenue 250,000 - 500,000 -

Grant and

fellowship

revenue
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014 PDL BioPharma, ... that in connection with the acquisition of Durata Therapeutics, ... in connection with the termination of PDL,s credit agreement ... amount outstanding of $40 million, accrued interest, and prepayment ... entered into a structured financing transaction with Durata in ...
(Date:11/17/2014)... The new METTLER TOLEDO White Paper " Traceability ... becoming the first calibration laboratory in the world ... the microgram range. National Metrology Institutes (NMI's), private ... in nanotechnology applications will benefit from understanding the ... weights in the range of 0.05 mg to ...
(Date:11/15/2014)... Burlington, MA (PRWEB) November 13, 2014 ... today announced they were named one of the Boston ... among the Medium Sized Businesses in Massachusetts to receive ... Work’ honors employers who take care of their most ... The awards are presented annually, and are based on ...
(Date:11/15/2014)... Denver, Colorado (PRWEB) November 14, 2014 ... leading provider of proprietary, cloud-based analytics, and scientific ... results for the third quarter ended September 30, ... Quarter 2014 Highlights, ,     CannLabs – ... in Las Vegas, Nevada. ,     CannLabs – ...
Breaking Biology Technology:PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2New White Paper on Microgram Weights Describes How to Achieve Traceable Measurement Down to 0.05 Milligrams 2Collaborative Consulting Honored with Boston Globe Top Places to Work 2014 2CannLabs Announces Third Quarter 2014 Results. 2CannLabs Announces Third Quarter 2014 Results. 3CannLabs Announces Third Quarter 2014 Results. 4CannLabs Announces Third Quarter 2014 Results. 5
... KANNAPOLIS, N.C. , May 26 The Immune ... Institute (DHMRI) today announced a collaboration to establish the Center ... H. Murdock Research Institute on the North Carolina Research Campus ... accelerate the discovery and development of new breakthrough treatments for ...
... 26 /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc.,(NYSE Amex: NBS ) ("NeoStem" or the "Company"), ... the Company,s Chief Executive Officer, Robin Smith , M.D., will,ring the opening bell ... 9:30 a.m. ET on Thursday, May 27, 2010 . , ... "We are honored to be back at ...
... CHICAGO , May 26 Advanced ... ADLS), a biopharmaceutical company engaged in the discovery, development and ... oncology and respiratory diseases, today announced positive results from ... the efficacy of Restanza™ (cethromycin), its novel oral antibiotic, against ...
Cached Biology Technology:The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 2The Immune Tolerance Institute and David H. Murdock Research Institute Announce a Partnership Establishing a State of the Art Human Immune Monitoring Laboratory for Biomarker Discovery and Development 3NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 2NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 3NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 2Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 3Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 4Advanced Life Sciences Announces Restanza(TM) Shows Efficacy Against Malaria 5
(Date:11/4/2014)... Medicine announced today that it is a Grand ... Bill & Melinda Gates Foundation. Laura Goetzl, ... Sciences; and Vice Chair of Research and Academic ... pursue an innovative global health and development research ... Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals worldwide ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... used chemical sleuthing to deduce what,s in fragranced consumer ... air wafting from household laundry vents. Findings, published online ... and Health, show that air vented from machines ... dryer sheet contains hazardous chemicals, including two that are ...
... Radiology,s flagship publication, the Journal of Vascular and ... arterial disease or PADcoinciding with the approach of September,s ... that Framingham Risk Score metrics (historically the gold standard ... enough to definitively say whether an individual may face ...
... from the University of Hawaii Cancer Center and The ... grant from the National Cancer Institute to develop novel ... joint analysis of gene expression and imaging data of ... Ph.D., a research scientist at the UH Cancer Center, ...
Cached Biology News:Scented laundry products emit hazardous chemicals through dryer vents 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 2Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 3Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 4Society of Interventional Radiology findings support PAD care; Legs For Life® gears up 5Hawaii receives funding for liver cancer research 2
... negatively supercoiled DNA in presence of EDTA ... of supercoiling on transcription in vitro , ... the degree of supercoiling of naturally occurring DNA ... length by only one base-pair , Increasing ...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
... Deletion Kit for Kilo-Sequencing is designed to ... cloned into the multiple cloning sites (MCS) ... plasmid or phagemid vectors (pUC18/19). The kit ... in the target DNA, thereby progressively moving ...
Applications: Immunohistochemistry, ISH, FISH, CISH....
Biology Products: